ΔΗΜΟΣΙΕΥΣΕΙΣ

A/A year Tumor Title Authors Journal Κέντρο Clinical or Lab
1 2002 All tumors Nonneutropenic febrile episodes associated with docetaxel-based chemotherapy in patients with solid tumors. Souglakos J, Kotsakis A, Kouroussis C, Kakolyris S, Mavroudis D, Kalbakis K, Agelaki S, Vlachonikolis J, Georgoulias V, Samonis G. Cancer EOEO Clinical
2 2002 All tumors Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors. Mavroudis D, Kouroussis Ch, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V. Oncology EOEO Clinical
3 2002 Breast Cancer Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. Koukourakis MI, Giatromanolaki A, Kouroussis C, Kakolyris S, Sivridis E, Frangiadaki C, Retalis G, Georgoulias V; Tumor and Angiogenesis Research Group. Int J Radiat Oncol Biol Phys EOEO Clinical
4 2002 Breast Cancer Incidence of breast cancer on Crete, 1994-1995. Vlachonikolis IG, Aletra TJ, Georgoulias V. Eur J Cancer EOEO Clinical
5 2002 Breast Cancer Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis Ch, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, Reppa D, Georgoulias V. J Clin Oncol EOEO Clinical
6 2002 Breast Cancer Phase I study of vinorelbine and carboplatin combination in patients with taxane and anthracycline pretreated advanced breast cancer. Kosmas C, Agelaki S, Giannakakis T, Mavroudis D, Kouroussis Ch, Kalbakis K, Papadouris S, Souglakos J, Malamos N, Georgoulias V. Oncology EOEO Clinical
7 2002 Colorectal Cancer Adjuvant systemic therapy protocol for Dukes’ B2 and C resectable colon carcinoma. Gennatas C, Mouratidou D, Androulakis G, Georgoulias V, Tsavaris N, Philippakis M, Michailakis E, Kalofonos C, Mpesmpeas S, Katsos J, Tsitoura M, Retalis G, Mallas E, Voros D, Andreadis C, Hatzistylianos G, Pisiotis C, Kamilarios D, Kakoliris S, Komporozos V, Kannas D, Legakis N, Mpatakis T, Ntamtsios J, Papaevangelou E, Peros G, Photopoulos A, Pouli A, Prigouris S, Samanidis L, Sakellariou V, Smyrniotis V, Polymeneas G, Vasiliou J, Athanasiou A, Papadimitriou J. Tumori EOEO Clinical
8 2002 Colorectal Cancer Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (de Gramont regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, Georgoulias V; Greek Colorectal Cooperative Oncology Group. Am J Clin Oncol EOEO Clinical
9 2002 Colorectal Cancer Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). Kouroussis C, Souglakos J, Mavroudis D, Papadouris S, Kakolyris S, Agelaki S, Kalbakis K, Panopoulos C, Vardakis N, Sarra E, Georgoulias V. Am J Clin Oncol EOEO Clinical
10 2002 Colorectal Cancer Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. Souglakos J, Mavroudis D, Kakolyris S, Kourousis Ch, Vardakis N, Androulakis N, Agelaki S, Kalbakis K, Tsetis D, Athanasiadis N, Samonis G, Georgoulias V. J Clin Oncol Laboratory UOC LAB
11 2002 NSCLC A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Kakolyris SS, Kouroussis C, Koukourakis M, Kalbakis K, Mavroudis D, Vardakis N,Georgoulias V. Anticancer Res POGK Clinical
12 2002 NSCLC A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer. Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V. Anticancer Res POGK clinical
13 2002 NSCLC Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Georgoulias V. Curr Med Chem review review
14 2002 NSCLC Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Georgoulias VA. Lung Cancer review review
15 2002 SCLC Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study. Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V; Hellenic Oncology Research Group. Lung Cancer review review
16 2003 All tumors A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Kouroussis C, Agelaki S, Mavroudis D, Kakolyris S, Androulakis N, Kalbakis K, Souglakos J, Mallas K, Bozionelou V, Pallis A, Adamtziki H, Georgoulias V. Anticancer Res EOEO Clinical
17 2003 All tumors A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M,Georgoulias V. Ann Oncol EOEO Clinical
18 2003 All tumors Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, Tsiftsis DD. Anticancer Res EOEO Clinical
19 2003 Breast Cancer A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer. Paridaens R, Van Aelst F, Georgoulias V, Samonnig H, Cocquyt V, Zielinski C, Hausmaninger H, Willemse P, Boudraa Y, Wildiers J, Ramazeilles C, Azli N. Ann Oncol EOEO Clinical
20 2003 Breast Cancer Development of a highly sensitive RT-PCR luminometric hybridization assay for human telomerase reverse-transcriptase beta-plus transcript. Angelopoulou K, Spiropoulou T, Stathopoulou A, Dimitroulopoulos D, Malamos N,Georgoulias V, Paraskevas E, Lianidou ES. Anticancer Res EOEO Clinical
21 2003 Breast Cancer Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study. Agelaki S, Karyda E, Kouroussis Ch, Ardavanis A, Kalbakis K, Malas K, Malamos N, Alexopoulos A, Tselepatiotis E, Georgoulias V. Oncology EOEO Clinical
22 2003 Breast Cancer Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Stathopoulou A, Mavroudis D, Perraki M, Apostolaki S, Vlachonikolis I, Lianidou E,Georgoulias V. Anticancer Res EOEO LAB
23 2003 Breast Cancer Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer. Xenidis N, Vlachonikolis I, Mavroudis D, Perraki M, Stathopoulou A, Malamos N, Kouroussis C, Kakolyris S, Apostolaki S, Vardakis N, Lianidou E, Georgoulias V. Ann Oncol EOEO LAB
24 2003 Breast Cancer Real-time quantification of CK-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D,Georgoulias V, Lianidou ES. Clin Cancer Res EOEO LAB
25 2003 Breast Cancer Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial. Mavroudis D, Alexopoulos A, Malamos N, Ardavanis A, Kandylis C, Stavrinidis E, Kouroussis Ch, Agelaki S, Androulakis N, Bozionelou V, Georgoulias V. Oncology Laboratory UOC LAB
26 2003 Colorectal Cancer Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Cascinu S, Georgoulias V, Kerr D, Maughan T, Labianca R, Ychou M. Ann Oncol POGK clinical
27 2003 Colorectal Cancer Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. Int J Radiat Oncol Biol Phys POGK clinical
28 2003 Lung Cancer Salmonella enterica pneumonia in a patient with lung cancer. Samonis G, Maraki S, Kouroussis C, Mavroudis D, Georgoulias V. J Clin Microbiol POGK clinical
29 2003 NSCLC Docetaxel versus docetaxel/cisplatin in patients with advanced non-small-cell lung cancer: preliminary analysis of a multicenter, randomized phase III study. Georgoulias V, Pallis AG, Kourousis C, Alexopoulos A, Ardavanis A, Agelidou A, Agelidou M, Toumbis M, Tzannes S, Pavlakou G, Ziotopoulos P, Tzelepatiotis E, Samaras N. Clin Lung Cancer POGK clinical
30 2003 NSCLC ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program. Pallis AG, Mavroudis D, Androulakis N, Souglakos J, Kouroussis C, Bozionelou V, Vlachonikolis IG, Georgoulias V. Lung Cancer POGK clinical
31 2003 Ovarian Cancer Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer. de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, Tsiftsis DD. Anticancer Drugs Διεθνείς συνεργασίες clinical
32 2003 Pancreatic Cancer Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Stathopoulos GP, Rigatos SK, Dimopoulos MA, Giannakakis T, Foutzilas G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG,Georgoulias V; Greek Cooperative Group for Pancreatic Cancer. Ann Oncol Διεθνείς συνεργασίες clinical
33 2003 SCLC Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study. Mavroudis D, Pavlakou G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas E, Samonis G, Georgoulias V. Lung Cancer Ελληνικές συνεργασίες clinical
34 2004 All tumors A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). Kalofonos HP, Kourousis C, Karamouzis MV, Iconomou G, Tsiata E, Tzorzidis F, Megas P, Lambiris E, Georgoulias V. Sarcoma EOEO Clinical
35 2004 All tumors Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Anatoliotaki M, Valatas V, Mantadakis E, Apostolakou H, Mavroudis D, Georgoulias V, Rolston KV, Kontoyiannis DP, Galanakis E, Samonis G. Infection EOEO Clinical
36 2004 All tumors Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. Kakolyris S, Souglakos J, Kouroussis C, Androulakis N, Samonis G, Vardakis N, Amarantidis K, Agelaki S, Mavroudis D, Xenidis N, Georgoulias V. Oncology EOEO Clinical
37 2004 Breast Cancer Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse. Giatromanolaki A, Koukourakis MI, Kakolyris S, Mavroudis D, Kouroussis C, Mavroudi C, Perraki M, Sivridis E, Georgoulias V. Int J Cancer EOEO Clinical
38 2004 Breast Cancer Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study. Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG). Oncology EOEO Clinical
39 2004 Breast Cancer Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson IC, Mellars L, Alland L, Tendler C. J Clin Oncol EOEO Clinical
40 2004 Breast Cancer Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V. Clin Cancer Res EOEO Clinical
41 2004 Gastric Cancer Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A, Georgoulias V. Ann Oncol EOEO Clinical
42 2004 NSCLC Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. Georgoulias V, Ardavanis A, Agelidou A, Agelidou M, Chandrinos V, Tsaroucha E, Toumbis M, Kouroussis C, Syrigos K, Polyzos A, Samaras N, Papakotoulas P, Christofilakis C, Ziras N, Alegakis A. J Clin Oncol EOEO LAB
43 2004 NSCLC Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Georgoulias V, Kouroussis C, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis E, Vlachonikolis I; Lung Cancer Committee of the Hellenic Oncology Research Group. Br J Cancer Laboratory UOC LAB
44 2004 Pancreatic Cancer Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V. Ann Oncol POGK clinical
45 2004 SCLC A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Agelaki S, Veslemes M, Syrigos K, Palamidas F, Polyzos A, Papakotoulas P, Kentepozidis N, Milaki G, Tzanakis N, Kouroussis C, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. Lung Cancer POGK clinical
46 2004 SCLC A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Agelaki S, Syrigos K, Christophylakis C, Boukovinas J, Varthalitis J, Pavlakou G, Athanasiadis A, Kouroussis C, Vardakis N, Maltezakis G, Milaki G, Georgoulias V; Lung Cancer Subgroup, Hellenic Oncology Research Group. Oncology Διεθνείς συνεργασίες clinical
47 2005 All tumors A dose escalating study of oxaliplatin and high dose weekly leucovorin and 5-Fluorouracil in patients with advanced solid tumors. Souglakos J, Kakolyris S, Vardakis N, Androulakis N, Mavroudis D, Vamvakas L, Kouroussis C, Agelaki S, Saridaki Z, Georgoulias V. Cancer Invest EOEO Clinical
48 2005 All tumors Micromolar taxol, with or without hyperthermia, induces mitotic catastrophe and cell necrosis in HeLa cells. Michalakis J, Georgatos SD, Romanos J, Koutala H, Georgoulias V, Tsiftsis D, Theodoropoulos PA. Cancer Chemother Pharmacol EOEO Clinical
49 2005 All tumors Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors. Kouroussis Ch, Androulakis N, Vamvakas L, Kalykaki A, Spiridonakou S, Kentepozidis N, Saridaki Z, Xiropoulou E, Georgoulias V. Oncology EOEO Clinical
50 2005 All tumors Teaching cancer management to primary care health staff: the first experiences gained from Crete. Lionis C, Samoutis G, Kouroussis C, Trigoni M, Georgoulias V. J Cancer Educ EOEO Clinical
51 2005 Breast Cancer Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status. Tsakountakis N, Sanidas E, Stathopoulos E, Kafousi M, Anogiannaki N,Georgoulias V, Tsiftsis DD. BMC Womens Health EOEO Clinical
52 2005 Breast Cancer Detection of CK-19 mRNA-positive cells in the peripheral blood of breast cancer patients with histologically and immunohistochemically negative axillary lymph nodes. Stathopoulos EN, Sanidas E, Kafousi M, Mavroudis D, Askoxylakis J, Bozionelou V, Perraki M, Tsiftsis D, Georgoulias V. Ann Oncol EOEO Clinical
53 2005 Colorectal Cancer Capecitabine as adjuvant treatment for stage III colon cancer. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. N Engl J Med EOEO Clinical
54 2005 Colorectal Cancer Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: a phase II trial. Souglakos J, Pallis A, Kakolyris S, Mavroudis D, Androulakis N, Kouroussis C, Agelaki S, Xenidis N, Milaki G, Georgoulias V. Oncology EOEO Clinical
55 2005 Colorectal Cancer Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: A phase II trial. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kouroussis Ch, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. J BUON EOEO Clinical
56 2005 Gastric Cancer Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Polyzos A, Syrigos K, Stergiou J, Panopoulos C, Potamianou A, Vamvakas L,Georgoulias V. Cancer Chemother Pharmacol EOEO Clinical
57 2005 NSCLC Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. Agelaki S, Georgoulias V. Expert Opin Emerg Drugs EOEO Clinical
58 2005 NSCLC Front-line treatment of advanced non-small cell lung cancer with irinotecan and docetaxel: a multicentre phase II study. Ziotopoulos P, Androulakis N, Mylonaki E, Chandrinos V, Zachariadis E, Boukovinas I, Agelidou A, Kentepozidis N, Ignatiadis M, Vossos A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG). Lung Cancer Laboratory UOC LAB
59 2005 NSCLC NSCLC–platinum or not. Androulakis N, Georgoulias V. Lung Cancer POGK clinical
60 2005 NSCLC Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Georgoulias V, Agelidou A, Syrigos K, Rapti A, Agelidou M, Nikolakopoulos J, Polyzos A, Athanasiadis A, Tselepatiotis E, Androulakis N, Kalbakis K, Samonis G, Mavroudis D. Br J Cancer POGK clinical
61 2005 NSCLC Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D. J Clin Oncol POGK clinical
62 2005 Ovarian Cancer Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Polyzos A, Kosmas C, Toufexi H, Malamos N, Lagadas A, Kosmidis C, Ginopoulos P, Ziras N, Kandilis K, Georgoulias V. Anticancer Res review review
63 2005 Ovarian Cancer Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Potamianou A, Androulakis N, Papakotoulas P, Toufexi H, Latoufis C, Kouroussis C, Christofilakis C, Xenidis N, Georgoulias V, Polyzos A. Oncology review review
64 2005 SCLC Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study. Rapti A, Agelidou A, Stergiou I, Agelidou M, Nikolakopoulos I, Varthalitis J, Kalykaki A, Chainis K, Tzanakis N, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group (HORG). Lung Cancer review review
65 2005 SCLC Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Ignatiadis M, Mavroudis D, Veslemes M, Boukovinas J, Syrigos K, Agelidou M, Agelidou A, Gerogianni A, Pavlakou G, Tselepatiotis E, Nikolakopoulos J,Georgoulias V. Clin Lung Cancer Διεθνείς συνεργασίες clinical
66 2006 All tumors A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors. Karampeazis A, Vamvakas L, Agelaki S, Kentepozidis N, Papadimitraki E, Gioulbasanis I, Vardakis N, Ignatiadis M, Mavroudis D, Georgoulias V. Oncology EOEO Clinical
67 2006 All tumors A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karampeazis A, Mavroudis D, Georgoulias V. Oncology EOEO Clinical
68 2006 All tumors A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors. Kotsakis A, Kouroussis Ch, Androulakis N, Agelaki S, Kalbakis K, Vamvakas L, Vardakis N, Kalykaki A, Polyzos A, Georgoulias V, Mavroudis D. Oncology EOEO Clinical
69 2006 All tumors A phase I study of the optimized cryptic peptide TERT(572y) in patients with advanced malignancies. Mavroudis D, Bolonakis I, Cornet S, Myllaki G, Kanellou P, Kotsakis A, Galanis A, Nikoloudi I, Spyropoulou M, Menez J, Miconnet I, Niniraki M, Cordopatis P, Kosmatopoulos K, Georgoulias V. Oncology EOEO Clinical
70 2006 All tumors Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine. Pappas P, Mavroudis D, Nikolaidou M, Georgoulias V, Marselos M. Anticancer Drugs EOEO Clinical
71 2006 All tumors Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Eur J Nucl Med Mol Imaging EOEO Clinical
72 2006 All tumors Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Koukouraki S, Strauss LG, Georgoulias V, Schuhmacher J, Haberkorn U, Karkavitsas N, Dimitrakopoulou-Strauss A. Eur J Nucl Med Mol Imaging EOEO Clinical
73 2006 All tumors Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulias V. Oncology EOEO Clinical
74 2006 All tumors Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, Mavroudis D, Georgoulias V. Ann Oncol EOEO Clinical
75 2006 Breast Cancer A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer. Stathopoulou A, Ntoulia M, Perraki M, Apostolaki S, Mavroudis D, Malamos N,Georgoulias V, Lianidou ES. Int J Cancer EOEO Clinical
76 2006 Breast Cancer Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status. Souglakos J, Vamvakas L, Apostolaki S, Perraki M, Saridaki Z, Kazakou I, Pallis A, Kouroussis C, Androulakis N, Kalbakis K, Millaki G, Mavroudis D, Georgoulias V. Breast Cancer Res EOEO Clinical
77 2006 Breast Cancer Detection of Mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Ntoulia M, Stathopoulou A, Ignatiadis M, Malamos N, Mavroudis D, Georgoulias V, Lianidou ES. Clin Biochem EOEO Clinical
78 2006 Breast Cancer HER-2 DNA quantification of paraffin-embedded breast carcinomas with LightCycler real-time PCR in comparison to immunohistochemistry and chromogenic in situ hybridization. Ntoulia M, Kaklamanis L, Valavanis C, Kafousi M, Stathopoulos E, Arapantoni P, Mavroudis D, Georgoulias V, Lianidou ES. Clin Biochem EOEO Clinical
79 2006 Breast Cancer Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study. Ardavanis A, Mavroudis D, Kalbakis K, Malamos N, Syrigos K, Vamvakas L, Kotsakis A, Kentepozidis N, Kouroussis C, Agelaki S, Georgoulias V; Breast Cancer Committee of the Hellenic Oncology Research Group. Cancer Chemother Pharmacol EOEO Clinical
80 2006 Breast Cancer Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients. Xenidis N, Perraki M, Kafousi M, Apostolaki S, Bolonaki I, Stathopoulou A, Kalbakis K, Androulakis N, Kouroussis C, Pallis T, Christophylakis C, Argyraki K, Lianidou ES, Stathopoulos S, Georgoulias V, Mavroudis D. J Clin Oncol EOEO Clinical
81 2006 Breast Cancer Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study. Kakolyris S, Kalbakis K, Potamianou A, Malamos N, Vamvakas L, Christophillakis C, Tselepatiotis E, Giassas S, Mavroudis D, Amarantidis K, Georgoulias V. Oncology EOEO LAB
82 2006 Breast Cancer Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulias V, Battelli N, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzelka L; Navelbine Herceptin Project. Br J Cancer EOEO LAB
83 2006 Colorectal Cancer FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D,Georgoulias V. Br J Cancer EOEO LAB
84 2006 Colorectal Cancer Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Ziras N, Potamianou A, Varthalitis I, Syrigos K, Tsousis S, Boukovinas I, Tselepatiotis E, Christofillakis C, Georgoulias V. Oncology EOEO LAB
85 2006 Colorectal Cancer VEGF expression in the colorectal adenoma-carcinoma sequence. Kaklamanis L, Trichas M, Amarantidis K, Spathari N, Micheli A, Karayiannakis A, Chatzaki E, Georgoulias V, Kakolyris S. Oncol Res Laboratory UOC LAB
86 2006 NSCLC A multicenter phase II study of sequential vinorelbine and cisplatin followed by docetaxel and gemcitabine in patients with advanced non-small cell lung cancer. Pallis AG, Agelidou A, Papakotoulas P, Tsaroucha A, Agelidou M, Agelaki S, Androulakis N, Vamvakas L, Gerogianni A, Kotsakis A, Kentepozidis N, Georgoulias V. Lung Cancer POGK clinical
87 2006 NSCLC A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V; Lung Cancer Group of the Hellenic Oncology Research Group. Clin Lung Cancer POGK clinical
88 2006 NSCLC Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Kakolyris S, Ziras N, Vamvakas L, Varthalitis J, Papakotoulas P, Syrigos K, Vardakis N, Kalykaki A, Amarantidis K, Georgoulias V. Lung Cancer POGK clinical
89 2006 NSCLC Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET. Dimitrakopoulou-Strauss A, Georgoulias V, Eisenhut M, Herth F, Koukouraki S, Mäcke HR, Haberkorn U, Strauss LG. Eur J Nucl Med Mol Imaging POGK clinical
90 2006 NSCLC Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Makrantonakis P, Ziotopoulos P, Agelidou A, Polyzos A, Ziras A, Chandrinos V, Vossos A, Kalykaki A, Androulakis N, Geroyianni A, Georgoulias V; Lung Cancer Committee of the Hellenic Oncology Research Group. Lung Cancer Διεθνείς συνεργασίες clinical
91 2006 Ovarian Cancer Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulias V, Tsiftsis DD. Eur J Surg Oncol Διεθνείς συνεργασίες clinical
92 2006 Pancreatic Cancer A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, Vamvakas L, Kotsakis A, Potamianou A, Georgoulias V. Oncology Διεθνείς συνεργασίες clinical
93 2006 Pancreatic Cancer A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. Br J Cancer Διεθνείς συνεργασίες clinical
94 2006 SCLC Cisplatin plus etoposide chemotherapy followed by thoracic irradiation and paclitaxel plus cisplatin consolidation therapy for patients with limited stage small cell lung carcinoma. Kakolyris S, Agelidou A, Androulakis N, Tsaroucha E, Kouroussis Ch, Agelidou M, Karvounis N, Veslemes M, Christophylakis Ch, Argyraki A, Geroyianni A,Georgoulias V. Lung Cancer Ελληνικές συνεργασίες clinical
95 2007 All tumors A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours. Bozionelou V, Vamvakas L, Pappas P, Agelaki S, Androulakis N, Kalykaki A, Nikolaidou M, Kentepozidis N, Giassas S, Marselos M, Georgoulias V, Mavroudis D. Br J Cancer EOEO Clinical
96 2007 All tumors Activation of FAK/PI3K/Rac1 signaling controls actin reorganization and inhibits cell motility in human cancer cells. Kallergi G, Agelaki S, Markomanolaki H, Georgoulias V, Stournaras C. Cell Physiol Biochem EOEO Clinical
97 2007 All tumors Short-term exposure of cancer cells to micromolar doses of paclitaxel, with or without hyperthermia, induces long-term inhibition of cell proliferation and cell death in vitro. Michalakis J, Georgatos SD, de Bree E, Polioudaki H, Romanos J, Georgoulias V, Tsiftsis DD, Theodoropoulos PA. Ann Surg Oncol EOEO Clinical
98 2007 Breast Cancer Circulating HER2 mRNA-positive cells in the peripheral blood of patients with stage I and II breast cancer after the administration of adjuvant chemotherapy: evaluation of their clinical relevance. Apostolaki S, Perraki M, Pallis A, Bozionelou V, Agelaki S, Kanellou P, Kotsakis A, Politaki E, Kalbakis K, Kalykaki A, Vamvakas L, Georgoulias V, Mavroudis D. Ann Oncol EOEO Clinical
99 2007 Breast Cancer Clinical relevance of circulating CK-19 mRNA-positive cells detected during the adjuvant tamoxifen treatment in patients with early breast cancer. Xenidis N, Markos V, Apostolaki S, Perraki M, Pallis A, Sfakiotaki G, Papadatos-Pastos D, Kalmanti L, Kafousi M, Stathopoulos E, Kakolyris S, Mavroudis D,Georgoulias V. Ann Oncol EOEO Clinical
100 2007 Breast Cancer Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D. J Clin Oncol EOEO LAB
101 2007 Breast Cancer Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer. Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D. Clin Breast Cancer EOEO LAB
102 2007 Breast Cancer Phosphorylation of FAK, PI-3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. Mol Med EOEO LAB
103 2007 Breast Cancer ProANP and NT-proBNP levels to prospectively assess cardiac function in breast cancer patients treated with cardiotoxic chemotherapy. Kouloubinis A, Kaklamanis L, Ziras N, Sofroniadou S, Makaritsis K, Adamopoulos S, Revela I, Athanasiou A, Mavroudis D, Georgoulias V. Int J Cardiol EOEO LAB
104 2007 Colorectal Cancer Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgoulias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G; European Colorectal Metastases Treatment Group. Eur J Cancer EOEO LAB
105 2007 Colorectal Cancer Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Maniadakis N, Pallis A, Fragoulakis V, Prezerakos P, Georgoulias V. Curr Med Res Opin Laboratory UOC LAB
106 2007 Colorectal Cancer Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E, Touroutoglou N, Chatzidakis A, Georgoulias V, Mavroudis D, Souglakos J. BMC Cancer Laboratory UOC LAB
107 2007 Colorectal Cancer Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial. Souglakos J, Vardakis N, Androulakis N, Kakolyris S, Kourousis C, Mavroudis D, Pallis A, Agelaki S, Kalbakis K, Georgoulias V. Dig Dis Laboratory UOC LAB
108 2007 Colorectal Cancer Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Souglakos J, Kalykaki A, Vamvakas L, Androulakis N, Kalbakis K, Agelaki S, Vardakis N, Tzardi M, Kotsakis AP, Gioulbasanis J, Tsetis D, Sfakiotaki G, Chatzidaki D, Mavroudis D, Georgoulias V. Ann Oncol POGK clinical
109 2007 Gastric Cancer Dose escalating clinical study of high dose infusional 5-fluorouracil and leukovorin (AIO regimen) plus alternate weekly administration of oxaliplatin and irinotecan in patients with advanced tumors of the gastrointestinal tract. Gkioulbasanis I, Souglakos J, Vardakis N, Kotsakis A, Saridaki Z, Kentepozidis N, Polyzos A, Giassas S, Ignatiadis M, Bozionelou V, Christophylakis C, Georgoulias V. J BUON POGK clinical
110 2007 NSCLC ‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M, Stathopoulos E, Mavroudis D, Georgoulias V. Br J Cancer POGK clinical
111 2007 NSCLC Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. Douillard JY, Laporte S, Fossella F, Georgoulias V, Pujol JL, Kubota K, Monnier A, Kudoh S, Rubio JE, Cucherat M. J Thorac Oncol POGK clinical
112 2007 NSCLC Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece. Maniadakis N, Fragoulakis V, Pallis A, Prezerakos P, Georgoulias V. Lung Cancer review review
113 2007 NSCLC Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial. Pallis AG, Christofillakis Ch, Tselepatiotis E, Agelaki S, Vamvakas L, Souglakos J, Vardakis N, Kalykaki A, Kotsakis A, Argiraki A, Mavroudis D, Georgoulias V. Lung Cancer review review
114 2007 NSCLC Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Koutsopoulos AV, Mavroudis D, Dambaki KI, Souglakos J, Tzortzaki EG, Drositis J, Delides GS, Georgoulias V, Stathopoulos EN. Lung Cancer Διεθνείς συνεργασίες clinical
115 2007 NSCLC Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide. Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D. J Clin Oncol Διεθνείς συνεργασίες clinical
116 2008 All tumors A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and oxaliplatin in patients with advanced solid tumors. Kalbakis K, Pappas P, Kouroussis C, Vamvakas L, Kalykaki A, Vardakis N, Nikolaidou M, Marselos M, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
117 2008 Breast Cancer Gefitinib in combination with gemcitabine and vinorelbine in patients with metastatic breast cancer pre-treated with taxane and anthracycline chemotherapy: a phase I/II trial. Gioulbasanis I, Saridaki Z, Kalykaki A, Vamvakas L, Kalbakis K, Ignatiadis M, Amarantidis K, Kakolyris S, Georgoulias V, Mavroudis D. Anticancer Res EOEO Clinical
118 2008 Breast Cancer Micrometastatic disease in breast cancer: clinical implications. Ignatiadis M, Georgoulias V, Mavroudis D. Eur J Cancer EOEO Clinical
119 2008 Breast Cancer Paclitaxel and docetaxel in the treatment of breast cancer. Saloustros E, Mavroudis D, Georgoulias V. Expert Opin Pharmacother EOEO Clinical
120 2008 Breast Cancer Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Breast Cancer Res EOEO Clinical
121 2008 Breast Cancer Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer. Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D. Clin Cancer Res EOEO LAB
122 2008 Colorectal Cancer Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Oncology EOEO LAB
123 2008 Lung Cancer Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V, Rosell R. Br J Cancer EOEO LAB
124 2008 NSCLC Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, Papakotoulas P, Agelidou A, Geroyianni A, Agelidou M, Hatzidaki D, Mavroudis D, Georgoulias V; Hellenic Oncology Research Group (HORG). Lung Cancer Laboratory UOC LAB
125 2008 NSCLC Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A. Br J Cancer Laboratory UOC LAB
126 2008 NSCLC Docetaxel in the treatment of advanced non-small-cell lung cancer. Saloustros E, Georgoulias V. Expert Rev Anticancer Ther Laboratory UOC LAB
127 2008 NSCLC Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial. Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Lung Cancer POGK clinical
128 2008 NSCLC Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. Pallis AG, Polyzos A, Boukovinas I, Agelidou A, Lamvakas L, Tsiafaki X, Agelidou M, Pavlakou G, Chandrinos V, Kakolyris S, Christophyllakis C, Kentepozidis N, Giassas S, Androulakis N, Agelaki S, Georgoulias V. J Thorac Oncol POGK clinical
129 2008 NSCLC Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, Lianidou ES. Clin Chem review review
130 2008 NSCLC Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R, Souglakos J. PLoS One review review
131 2008 Ovarian Cancer Gemcitabine plus oxaliplatin (GEMOX) in pretreated patients with advanced ovarian cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Kalykaki A, Papakotoulas P, Tsousis S, Boukovinas I, Kalbakis K, Vamvakas L, Kotsakis A, Vardakis N, Papadopoulou P, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Anticancer Res review review
132 2008 Pancreatic Cancer Present treatment and future expectations in advanced pancreatic cancer. Stathopoulos GP, Androulakis N, Souglakos J, Stathopoulos J, Georgoulias V. Anticancer Res review review
133 2009 All tumors A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors. Saridaki Z, Pappas P, Souglakos J, Nikolaidou M, Vardakis N, Kotsakis A, Marselos M, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
134 2009 Breast Cancer A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A,Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
135 2009 Breast Cancer Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition. Agelaki S, Spiliotaki M, Markomanolaki H, Kallergi G, Mavroudis D, Georgoulias V, Stournaras C. Cancer Biol Ther EOEO LAB
136 2009 Breast Cancer Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D. J Clin Oncol EOEO LAB
137 2009 Breast Cancer Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V. Br J Cancer EOEO LAB
138 2009 Breast Cancer Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance. Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D. Breast Cancer Res Treat EOEO LAB
139 2009 Breast Cancer Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES,Georgoulias V, Mavroudis D, Agelaki S. Breast Cancer Res Laboratory UOC LAB
140 2009 Breast Cancer Kallikrein 10 (KLK10) methylation as a novel prognostic biomarker in early breast cancer. Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES. Ann Oncol Laboratory UOC LAB
141 2009 Breast Cancer Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D,Georgoulias V, Lianidou ES. Int J Cancer Laboratory UOC LAB
142 2009 Breast Cancer Prognostic significance of RASSF1A promoter methylation in operable breast cancer. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES. Clin Biochem Laboratory UOC LAB
143 2009 Colorectal Cancer Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S, Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH, Shivdasani RA. Br J Cancer Laboratory UOC LAB
144 2009 Colorectal Cancer Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D; First BEAT investigators. Ann Oncol Laboratory UOC LAB
145 2009 Lung Cancer Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study. Boukovinas I, Souglakos J, Hatzidaki D, Kakolyris S, Ziras N, Vamvakas L, Polyzos A, Geroyianni A, Agelidou A, Agelaki S, Kalbakis K, Kotsakis A, Mavroudis D,Georgoulias V. Lung Cancer POGK clinical
146 2009 Lung Cancer Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J. Clin Cancer Res POGK clinical
147 2009 NSCLC Advanced non-small-cell lung cancer in the elderly. Vamvakas L, Saloustros E, Karampeazis A, Georgoulias V. Clin Lung Cancer POGK clinical
148 2009 NSCLC Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. Kouroussis C, Vamvakas L, Vardakis N, Kotsakis A, Kalykaki A, Kalbakis K, Saridaki Z, Kentepozidis N, Giassas S, Georgoulias V. Oncology review review
149 2009 NSCLC DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, Mavroudis D. Clin Lung Cancer Διεθνείς συνεργασίες clinical
150 2009 NSCLC Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C. J Clin Oncol Διεθνείς συνεργασίες clinical
151 2009 SCLC A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer. Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, Rapti A, Chandrinos V, Christophyllakis C, Georgoulias V. Lung Cancer Διεθνείς συνεργασίες clinical
152 2010 All tumors A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Karachaliou N, Polyzos A, Kentepozidis N, Kakolyris S, Ziras N, Vardakis N, Kalykaki A, Milaki G, Georgoulias V, Androulakis N. Oncology EOEO Clinical
153 2010 All tumors Favorable clinical course of patients experiencing bevacizumab-induced proteinuria. Saloustros E, Androulakis N, Vamvakas L, Mavroudis D, Georgoulias V. Case Rep Oncol (karger) EOEO Clinical
154 2010 All tumors PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. J Mol Diagn EOEO Clinical
155 2010 Breast Cancer Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Breast Cancer Res Treat EOEO Clinical
156 2010 Breast Cancer Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Theodoropoulos PA, Polioudaki H, Agelaki S, Kallergi G, Saridaki Z, Mavroudis D,Georgoulias V. Cancer Lett EOEO Clinical
157 2010 Breast Cancer Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. Mauri D, Valachis A, Polyzos NP, Tsali L, Mavroudis D, Georgoulias V, Casazza G. J Natl Compr Canc Netw EOEO Clinical
158 2010 Breast Cancer FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Breast Cancer Res Treat EOEO Clinical
159 2010 Breast Cancer Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Crit Rev Oncol Hematol EOEO Clinical
160 2010 Breast Cancer Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: a meta-analysis. Valachis A, Polyzos NP, Georgoulias V, Mavroudis D, Mauri D. Gynecol Oncol Laboratory UOC LAB
161 2010 Breast Cancer Partial breast irradiation or whole breast radiotherapy for early breast cancer: a meta-analysis of randomized controlled trials. Valachis A, Mauri D, Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Breast J (Wiley Online Library) Laboratory UOC LAB
162 2010 Breast Cancer Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer. Karachaliou N, Saloustros E, Vamvakas L, Mavroudis D, Georgoulias V. Ann Oncol Laboratory UOC LAB
163 2010 Breast Cancer Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N,Georgoulias V; Breast Cancer Investigators of the Hellenic Oncology Research Group. Ann Oncol Laboratory UOC LAB
164 2010 Colorectal Cancer BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J. Br J Cancer review review
165 2010 Colorectal Cancer Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). Vamvakas L, Athanasiadis A, Karampeazis A, Kakolyris S, Polyzos A, Kouroussis Ch, Ziras N, Kalbakis K, Georgoulias V, Souglakos J. Crit Rev Oncol Hematol review review
166 2010 Colorectal Cancer Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. Saridaki Z, Georgoulias V, Souglakos J. World J Gastroenterol review review
167 2010 Head and Neck Cancer Anti-CV2 associated cerebellar degeneration after complete response to chemoradiation of head and neck carcinoma. Saloustros E, Zaganas I, Mavridis M, Vamvakas L, Plaitakis A, Georgoulias V, Mavroudis D. J Neurooncol review review
168 2010 NSCLC A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V. Cancer Chemother Pharmacol review review
169 2010 NSCLC A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. Pallis AG, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N, Pavlakou G, Kotsakis A, Kontopodis E, Georgoulias V. BMC Cancer review review
170 2010 NSCLC Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials. Di Maio M, Lama N, Morabito A, Smit EF, Georgoulias V, Takeda K, Quoix E, Hatzidaki D, Wachters FM, Gebbia V, Tsai CM, Camps C, Schuette W, Chiodini P, Piccirillo MC, Perrone F, Gallo C, Gridelli C. Eur J Cancer review review
171 2010 NSCLC Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V, Voutsina A. Lung Cancer review review
172 2010 NSCLC Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Maniadakis N, Fragoulakis V, Pallis AG, Simou E, Georgoulias V. Ann Oncol review review
173 2010 NSCLC Non-platinum-based first-line followed by platinum-based second-line chemotherapy or the reverse sequence in patients with advanced non-small cell lung cancer: a retrospective analysis by the lung cancer group of the Hellenic Oncology Research Group. Agelaki S, Hatzidaki D, Kotsakis A, Papakotoulas P, Polyzos A, Ziras N, Gioulbasanis I, Karampeazis A, Agelidou A, Tsiafaki X, Chandrinos V, Lerikou M, Georgoulias V. Oncology review review
174 2010 NSCLC Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer. Kotsakis A, Georgoulias V. Expert Opin Pharmacother review review
175 2010 SCLC Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study. Xenidis N, Kotsakis A, Kalykaki A, Christophyllakis Ch, Giassas S, Kentepozidis N, Polyzos A, Chelis L, Vardakis N, Vamvakas L, Georgoulias V, Kakolyris S. Lung Cancer Διεθνείς συνεργασίες clinical
176 2011 All tumors Prophylactic and therapeutic strategies in chemotherapy-induced neutropenia. Saloustros E, Tryfonidis K, Georgoulias V. Expert Opin Pharmacother EOEO Clinical
177 2011 All tumors Sequential administration of the native TERT572 cryptic peptide enhances the immune response initiated by its optimized variant TERT(572Y) in cancer patients. Vetsika EK, Papadimitraki E, Aggouraki D, Konsolakis G, Mela ME, Kotsakis A, Christou S, Patramani S, Alefantinou M, Kaskara A, Christophyllakis C, Kosmatopoulos K, Georgoulias V, Mavroudis D. J Immunother EOEO Clinical
178 2011 Breast Cancer Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection. Daskalakis M, Mavroudis D, Sanidas E, Apostolaki S, Askoxylakis I, de Bree E,Georgoulias V, Melissas J. Eur J Surg Oncol EOEO Clinical
179 2011 Breast Cancer Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse. Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D. Breast Cancer Res EOEO Clinical
180 2011 Breast Cancer DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Chimonidou M, Strati A, Tzitzira A, Sotiropoulou G, Malamos N, Georgoulias V, Lianidou ES. Clin Chem EOEO Clinical
181 2011 Breast Cancer Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Kallergi G, Papadaki MA, Politaki E, Mavroudis D, Georgoulias V, Agelaki S. Breast Cancer Res EOEO Clinical
182 2011 Breast Cancer Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. Strati A, Markou A, Parisi C, Politaki E, Mavroudis D, Georgoulias V, Lianidou E. BMC Cancer EOEO Clinical
183 2011 Breast Cancer Metronomic vinorelbine plus bevacizumab as salvage therapy for patients with metastatic breast cancer. Saloustros E, Kalbakis K, Vardakis N, Kalykaki A, Milaki G, Rovithi M, Agelaki S, Saridaki Z, Georgoulias V, Mavroudis D. J BUON EOEO LAB
184 2011 Breast Cancer Molecular characterization of circulating tumor cells in breast cancer by a liquid bead array hybridization assay. Markou A, Strati A, Malamos N, Georgoulias V, Lianidou ES. Clin Chem EOEO LAB
185 2011 Breast Cancer Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab. Polyzos A, Kalbakis K, Kentepozidis N, Giassas S, Kalykaki A, Vardakis N, Bozionelou V, Saloustros E, Kontopodis E, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO LAB
186 2011 Breast Cancer Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V. Breast (Elsevier) EOEO LAB
187 2011 Colorectal Cancer Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. Saridaki Z, Tzardi M, Papadaki C, Sfakianaki M, Pega F, Kalikaki A, Tsakalaki E, Trypaki M, Messaritakis I, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. PLoS One EOEO LAB
188 2011 Colorectal Cancer Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer. Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J. Clin Cancer Res Laboratory UOC LAB
189 2011 Head and Neck Cancer Hypofractionated accelerated CT-guided interstitial ¹⁹²Ir-HDR-Brachytherapy as re-irradiation in inoperable recurrent cervical lymphadenopathy from head and neck cancer. Tselis N, Ratka M, Vogt HG, Kolotas C, Baghi M, Baltas D, Fountzilas G,Georgoulias V, Ackermann H, Zamboglou N. Radiother Oncol Laboratory UOC LAB
190 2011 Lung Cancer Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Gioulbasanis I, Baracos VE, Giannousi Z, Xyrafas A, Martin L, Georgoulias V, Mavroudis D. Ann Oncol Laboratory UOC LAB
191 2011 Lung Cancer Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, Papandreou CN, Mavroudis D, Georgoulias V. Lung Cancer Laboratory UOC LAB
192 2011 NSCLC A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Kotsakis A, Agelaki S, Vardakis N, Stathopoulos G, Vamvakas L, Kalykaki A, Kentepozidis N, Kontopodis E, Sfakiotaki G, Mavroudis D, Georgoulias V. Cancer Chemother Pharmacol Laboratory UOC LAB
193 2011 NSCLC A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Pallis AG, Chandrinos V, Pavlakou G, Xenidis N, Varthalitis I, Vardakis N, Vamvakas L, Kontopodis E, Rovithi M, Georgoulias V. Cancer Chemother Pharmacol POGK clinical
194 2011 NSCLC Baseline insulin-like growth factor-I plasma levels, systemic inflammation, weight loss and clinical outcome in metastatic non-small cell lung cancer patients. Vlachostergios PJ, Gioulbasanis I, Kamposioras K, Georgoulias P, Baracos VE, Ghosh S, Maragouli E, Georgoulias V, Papandreou CN. Oncology POGK clinical
195 2011 NSCLC Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. Br J Cancer POGK clinical
196 2011 NSCLC Docetaxel vs. vinorelbine in elderly patients with advanced non–small-cell lung cancer: a hellenic oncology research group randomized phase III study. Karampeazis A, Vamvakas L, Agelidou A, Kentepozidis N, Chainis K, Chandrinos V, Vardakis N, Pallis AG, Christophyllakis C, Georgoulias V. Clin Lung Cancer POGK clinical
197 2011 NSCLC Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. Pallis AG, Karampeazis A, Vamvakas L, Vardakis N, Kotsakis A, Bozionelou V, Kalykaki A, Hatzidaki D, Mavroudis D, Georgoulias V. Ann Oncol review review
198 2011 NSCLC How close are we to customizing chemotherapy in early non-small cell lung cancer? Ioannidis G, Georgoulias V, Souglakos J. Ther Adv Med Oncol review review
199 2011 NSCLC Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study. Pallis AG, Syrigos K, Kotsakis A, Karachaliou N, Polyzos A, Chandrinos V, Varthalitis I, Christophyllakis C, Ardavanis A, Vamvakas L, Vardakis N, Saridaki Z, Samonis G, Giassas S, Georgoulias V, Agelaki S. Clin Lung Cancer review review
200 2011 NSCLC Targeting the insulin-like growth factor I receptor inhibits proliferation and VEGF production of non-small cell lung cancer cells and enhances paclitaxel-mediated anti-tumor effect. Spiliotaki M, Markomanolaki H, Mela M, Mavroudis D, Georgoulias V, Agelaki S. Lung Cancer review review
201 2011 Ovarian Cancer Small cell ovarian cancer in adolescents: report of two cases and review of the literature. Rovithi M, Pallis AG, Kalykaki A, Lagoudaki E, Giannikaki L, Stathopoulos EN, Relakis K, Georgoulias V. Case Rep Med review review
202 2011 Pancreatic Cancer Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V. Cancer Chemother Pharmacol review review
203 2011 SCLC Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration. Stylianou K, Lioudaki E, Papadimitraki E, Kokologiannakis G, Kroustalakis N, Liotsi C, Giannakakis K, Georgoulias V, Daphnis E. Nephrol Dial Transplant review review
204 2011 SCLC Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer. Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K, Georgoulias V. Cancer Chemother Pharmacol Διεθνείς συνεργασίες clinical
205 2012 All tumors A closed-tube methylation-sensitive high resolution melting assay (MS-HRMA) for the semi-quantitative determination of CST6 promoter methylation in clinical samples. Dimitrakopoulos L, Vorkas PA, Georgoulias V, Lianidou ES. BMC Cancer EOEO Clinical
206 2012 All tumors Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V. Cancer Chemother Pharmacol EOEO Clinical
207 2012 All tumors Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study. Kotsakis A, Vetsika EK, Christou S, Hatzidaki D, Vardakis N, Aggouraki D, Konsolakis G, Georgoulias V, Christophyllakis Ch, Cordopatis P, Kosmatopoulos K, Mavroudis D. Ann Oncol EOEO Clinical
208 2012 All tumors Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001. Vetsika EK, Konsolakis G, Aggouraki D, Kotsakis A, Papadimitraki E, Christou S, Menez-Jamet J, Kosmatopoulos K, Georgoulias V, Mavroudis D. Cancer Immunol Immunother EOEO Clinical
209 2012 All tumors Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside TL. J Immunol Methods EOEO Clinical
210 2012 All tumors Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study. Kentepozidis N, Soultati A, Giassas S, Vardakis N, Kalykaki A, Kotsakis A, Papadimitraki E, Pantazopoulos N, Bozionellou V, Georgoulias V. Cancer Chemother Pharmacol EOEO Clinical
211 2012 Breast Cancer A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Karachaliou N, Ziras N, Syrigos K, Tryfonidis K, Papadimitraki E, Kontopodis E, Bozionelou V, Kalykaki A, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
212 2012 Breast Cancer A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer. Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
213 2012 Breast Cancer A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D. Ann Oncol EOEO Clinical
214 2012 Breast Cancer A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. Saridaki Z, Malamos N, Kourakos P, Polyzos A, Ardavanis A, Androulakis N, Kalbakis K, Vamvakas L, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
215 2012 Breast Cancer Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V. Br J Cancer EOEO LAB
216 2012 Breast Cancer Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D. Ann Oncol EOEO LAB
217 2012 Colorectal Cancer A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J. Br J Cancer Laboratory UOC LAB
218 2012 Colorectal Cancer Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, Xynogalos S, Christophyllakis Ch, Kouroussis Ch, Vamvakas L, Georgoulias V, Polyzos A. Br J Cancer Laboratory UOC LAB
219 2012 Lung Cancer Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. Giannousi Z, Gioulbasanis I, Pallis AG, Xyrafas A, Dalliani D, Kalbakis K, Papadopoulos V, Mavroudis D, Georgoulias V, Papandreou CN. Support Care Cancer Laboratory UOC LAB
220 2012 Lung Cancer The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D, Georgoulias V. Lung Cancer Laboratory UOC LAB
221 2012 NSCLC A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, Tryfonidis K, Kotsakis A, Vamvakas L, Vardakis N, Georgoulias V. Clin Lung Cancer Laboratory UOC LAB
222 2012 NSCLC Baseline plasma levels of interleukin-8 in stage IV non-small-cell lung cancer patients: relationship with nutritional status and prognosis. Gioulbasanis I, Patrikidou A, Kitikidou K, Papadimitriou K, Vlachostergios PJ, Tsatsanis C, Margioris AN, Papandreou CN, Mavroudis D, Georgoulias V. Nutr Cancer POGK clinical
223 2012 NSCLC ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer. Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. J Thorac Oncol review review
224 2012 NSCLC Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today’s standard of care. Pallis AG, Georgoulias V. Lung Cancer review review
225 2012 NSCLC Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold Ch, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC; Central European Cooperative Oncology Group (CECOG). Ann Oncol Διεθνείς συνεργασίες clinical
226 2012 SCLC Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group. Mountzios G, Emmanouilidis C, Vardakis N, Kontopodis E, Hatzidaki D, Popis E, Karachaliou N, Kotsakis A, Agelidou M, Georgoulias V. Lung Cancer Διεθνείς συνεργασίες clinical
227 2013 Breast Cancer A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. Tryfonidis K, Boukovinas I, Xenidis N, Christophyllakis C, Papakotoulas P, Politaki E, Malamos N, Polyzos A, Kakolyris S, Georgoulias V, Mavroudis D; Hellenic Oncology Research Group. Breast (Elsevier) EOEO Clinical
228 2013 Breast Cancer Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Kallergi G, Konstantinidis G, Markomanolaki H, Papadaki MA, Mavroudis D, Stournaras C, Georgoulias V, Agelaki S. Mol Cancer Ther EOEO Clinical
229 2013 Breast Cancer Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Chimonidou M, Kallergi G, Georgoulias V, Welch DR, Lianidou ES. Mol Cancer Res EOEO Clinical
230 2013 Breast Cancer Clinical challenges in the molecular characterization of circulating tumour cells in breast cancer. Lianidou ES, Mavroudis D, Georgoulias V. Br J Cancer EOEO Clinical
231 2013 Breast Cancer CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N,Georgoulias V, Lianidou E. Clin Biochem EOEO Clinical
232 2013 Breast Cancer Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V. Br J Cancer EOEO LAB
233 2013 Breast Cancer PIK3CA hotspot mutation scanning by a novel and highly sensitive high-resolution small amplicon melting analysis method. Vorkas PA, Poumpouridou N, Agelaki S, Kroupis C, Georgoulias V, Lianidou ES. J Mol Diagn EOEO LAB
234 2013 Breast Cancer SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES. Clin Chem Laboratory UOC LAB
235 2013 Colorectal Cancer BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. PLoS One Laboratory UOC LAB
236 2013 Colorectal Cancer Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, Mavroudis D, Georgoulias V. Mod Pathol Laboratory UOC LAB
237 2013 Gastric Cancer Postoperative Treatment With Docetaxel, Cisplatin, and Capecitabine (DCX) and Chemoradiotherapy (CRT) With Capecitabine for Resected Gastric Adenocarcinoma. Saridaki Z, Lambrodimou G, Kachris S, Makrantonakis P, Boukovinas I, Polyzos A, Anagnostopoulos A, Athanasiadis A, Stoltidis D, Georgoulias V, Souglakos J. Am J Clin Oncol Laboratory UOC LAB
238 2013 NSCLC A multicenter randomized phase IIb efficacy study of Vx-001, a peptide-based cancer vaccine as maintenance treatment in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics. Georgoulias V, Douillard JY, Khayat D, Manegold C, Rosell R, Rossi A, Menez-Jamet J, Iché M, Kosmatopoulos K, Gridelli C. Clin Lung Cancer Laboratory UOC LAB
239 2013 NSCLC Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V. Cancer Chemother Pharmacol Laboratory UOC LAB
240 2013 NSCLC Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D. Lung Cancer Laboratory UOC LAB
241 2013 NSCLC Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, Kotsakis A, Papakotoulas P, Rapti A, Agelidou M, Agelaki S, Vamvakas L, Samonis G, Mavroudis D, Georgoulias V. Cancer Laboratory UOC LAB
242 2013 NSCLC Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials. Laporte S, Squifflet P, Baroux N, Fossella F, Georgoulias V, Pujol JL, Douillard JY, Kudoh S, Pignon JP, Quinaux E, Buyse M. BMJ Open review review
243 2013 SCLC A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Agelaki S, Kontopodis E, Kotsakis A, Chandrinos V, Bompolaki I, Zafeiriou Z, Papadimitraki E, Stoltidis D, Kalbakis K, Georgoulias V. Cancer Chemother Pharmacol Διεθνείς συνεργασίες clinical
244 2013 SCLC Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide. Karachaliou N, Papadaki C, Lagoudaki E, Trypaki M, Sfakianaki M, Koutsopoulos A, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. PLoS One Διεθνείς συνεργασίες clinical
245 2014 All tumors Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer. Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR,Georgoulias V, Lianidou ES. Br J Cancer case report clinical
246 2014 All tumors Plasmablastic Lymphoma of the Breast in an Immunocompetent Patient: Long-lasting Complete Response Induced by Chemotherapy and Autologous Stem Cell Trasplantation. Matikas A, Kanellis G, Papadimitriou C, Papadaki T, Kotsakis A, Dimopoulos MA,Georgoulias V. Anticancer Res. EOEO Clinical
247 2014 Breast Cancer A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype. Fostira F, Tsoukalas N, Konstantopoulou I, Georgoulias V, Christophyllakis C, Yannoukakos D. Case Rep Genet. EOEO Clinical
248 2014 Breast Cancer Detection of Circulating Cytokeratin-19 mRNA-Positive Cells in the Blood and the Mitotic Index of the Primary Tumor Have Independent Prognostic Value in Early Breast Cancer. Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E, Mavroudis D. Clin Breast Cancer. EOEO Clinical
249 2014 Breast Cancer Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib. Kalykaki A, Agelaki S, Kallergi G, Xyrafas A, Mavroudis D, Georgoulias V. Cancer Chemother Pharmacol. EOEO LAB
250 2014 Breast Cancer Prognostic significance of metastasis-related microRNAs in early breast cancer patients with a long follow-up. Markou A, Yousef GM, Stathopoulos E, Georgoulias V, Lianidou E. Clin Chem Laboratory UOC LAB
251 2014 Colorectal Cancer BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients’ outcome. Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, Messaritakis I, Mpananis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J. PLoS One Laboratory UOC LAB
252 2014 Colorectal Cancer Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Vamvakas L, Matikas A, Karampeazis A, Hatzidaki D, Kakolyris S, Christophylakis C, Boukovinas I, Polyzos A, Georgoulias V, Souglakos J. BMC Cancer Laboratory UOC LAB
253 2014 Colorectal Cancer KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulias V, Voutsina A. PLoS One Laboratory UOC LAB
254 2014 Colorectal Cancer Prognostic and predictive significance of MSI in stages II/III colon cancer. Saridaki Z, Souglakos J, Georgoulias V. World J Gastroenterol. Laboratory UOC LAB
255 2014 Lung Cancer Lung cancer in the era of Greek economic crisis. Saloustros E, Vichas G, Margiolaki A, Koumiotaki S, Androulakis N, Georgoulias V. Laboratory UOC LAB
256 2014 NSCLC A phase II trial evaluating the clinical and immunologic response of HLA-A2+ non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D, Georgoulias V. Lung Cancer Laboratory UOC LAB
257 2014 NSCLC PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, Tsakalaki E, Voutsina A, Koutsopoulos A, Mavroudis D, Georgoulias V, Souglakos J. Br J Cancer review review
258 2014 Ovarian Cancer Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomiak E, Grynspan D, Saloustros E, Nadaf J, Rivera B, Gilpin C, Castellsagué E, Silva-Smith R, Plourde F, Wu M, Saskin A, Arseneault M, Karabakhtsian RG, Reilly EA, Ueland FR, Margiolaki A, Pavlakis K, Castellino SM, Lamovec J, Mackay HJ, Roth LM, Ulbright TM, Bender TA, Georgoulias V, Longy M, Berchuck A, Tischkowitz M, Nagel I, Siebert R, Stewart CJ, Arseneau J, McCluggage WG, Clarke BA, Riazalhosseini Y, Hasselblatt M, Majewski J, Foulkes WD. Nat Genet. review review
259 2014 Ovarian Cancer Salvage chemotherapy with docetaxel and pegylated liposomal doxorubicin in pretreated patients with platinum- and taxane-sensitive ovarian cancer: a multicenter phase II trial of the Hellenic Oncology Research Group (HORG). Koinis F, Polyzos A, Christopoulou A, Zafeiriou Z, Emmanouilidis C, Papadimitraki E, Kalykaki A, Kalbakis K, Samonis G, Georgoulias V. Cancer Chemother Pharmacol. review review
260 2014 Pancreatic Cancer Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Katopodis O, Souglakos J, Stathopoulos E, Christopoulou A, Kontopodis E, Kotsakis A, Kalbakis K, Kentepozidis N, Polyzos A, Hatzidaki D, Georgoulias V. Cancer Chemother Pharmacol. Διεθνείς συνεργασίες clinical
261 2015 All tumors A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E. Clin Chim Acta. Athens Laboratory lab
262 2015 All tumors A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples. Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E. Clin Chim Acta. EOEO Clinical
263 2015 All tumors Metastasis-related miRNAs: a new way to differentiate patients with higher risk? Markou A, Lianidou E, Georgoulias V. Future Oncol. EOEO Clinical
264 2015 All tumors Metastasis-related miRNAs: a new way to differentiate patients with higher risk? Markou A, Lianidou E, Georgoulias V. Future Oncol. EOEO Clinical
265 2015 Breast Cancer Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer. Kontopodis E, Kentepozidis N, Christophyllakis Ch, Boukovinas I, Kalykaki A, Kalbakis K, Vamvakas L, Agelaki S, Kotsakis A, Vardakis N, Georgoulias V, Mavroudis D. Cancer Chemother Pharmacol EOEO Clinical
266 2015 Breast Cancer Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Saloustros E, Malamos N, Boukovinas I, Kakolyris S, Kouroussis C, Athanasiadis A, Ziras N, Kentepozidis N, Makrantonakis P, Polyzos A, Christophyllakis C, Georgoulias V, Mavroudis D. Breast Cancer Res Treat EOEO Clinical
267 2015 Breast Cancer Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer. Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D. Cancer Chemother Pharmacol EOEO LAB
268 2015 Breast Cancer Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer. Agelaki S, Kalykaki A, Markomanolaki H, Papadaki MA, Kallergi G, Hatzidaki D, Kalbakis K, Mavroudis D, Georgoulias V PLoS One EOEO Clinical
269 2015 Breast Cancer Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy. Spiliotaki M, Mavroudis D, Kapranou K, Markomanolaki H, Kallergi G, Koinis F, Kalbakis K,Georgoulias V, Agelaki S. Breast Cancer Res EOEO Clinical
270 2015 Breast Cancer Expression of truncated human epidermal growth factor receptor 2 on circulating tumor cells of breast cancer patients. Kallergi G, Agelaki S, Papadaki MA, Nasias D, Matikas A, Mavroudis D, Georgoulias V. Breast Cancer Res. EOEO Clinical
271 2015 Breast Cancer PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E. Clin Cancer Res Laboratory UOC LAB
272 2015 Breast Cancer Six versus twelve months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V Ann Oncol Laboratory UOC LAB
273 2015 Breast Cancer Six versus twelve months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: A multicenter randomized study by the Hellenic Oncology Research Group (HORG). Mavroudis D, Saloustros E, Malamos N, Kakolyris S, Boukovinas I, Papakotoulas P, Kentepozidis N, Ziras N, Georgoulias V Ann Oncol. 2015 May 1. pii: mdv213. [Epub ahead of print] Laboratory UOC LAB
274 2015 Colorectal Cancer The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. Cancers (Basel). Laboratory UOC LAB
275 2015 Colorectal Cancer The Place of Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer. Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. Cancers (Basel). Laboratory UOC LAB
276 2015 NSCLC A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, Mavroudis D,Georgoulias V, Kotsakis A. J Immunol Res Laboratory UOC LAB
277 2015 NSCLC Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. Cancer Chemother Pharmacol Laboratory UOC LAB
278 2015 NSCLC Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Katsaounis P, Kotsakis A, Agelaki S, Kontopodis E, Agelidou A, Kentepozidis N, Vamvakas L, Christopoulou A, Karachaliou N, Hatzidaki D, Georgoulias V. Cancer Chemother Pharmacol review review
279 2015 NSCLC Current and Future Approaches in the Management of Non-Small-Cell Lung Cancer Patients With Resistance to EGFR TKIs. Matikas A, Mistriotis D, Georgoulias V, Kotsakis A. Clin Lung Cancer review review
280 2015 NSCLC ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, Xyrafas A, Kotsakis A, Agelaki S, Souglakos J, Mavroudis D, Georgoulias V Cancer Invest. review review
281 2015 NSCLC Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer. Syrios J, Nintos G, Georgoulias V Expert Rev Anticancer Ther. review review
282 2015 NSCLC Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. Lung Cancer review review
283 2015 NSCLC Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG). Kotsakis A, Kentepozidis N, Emmanouilidis Ch, Polyzos A, Agelidou A, Vaslamatzis M, Chandrinos V, Agelaki S, Vamvakas L, Kalbakis K, Katsaounis P, Stoltidis D, Nintos G, Hatzidaki D, Vetsika EK, Mavroudis D, Georgoulias V. Lung Cancer. review review
284 2016 Breast Cancer Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG). Mavroudis D, Matikas A, Malamos N, Papakotoulas P, Kakolyris S, Boukovinas I, Athanasiadis A, Kentepozidis N, Ziras N, Katsaounis P, Saloustros E, Georgoulias V Ann Oncol. EOEO Clinical
285 2016 NSCLC A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy. Kotsakis A, Matikas A, Koinis F, Kentepozidis N, Varthalitis II, Karavassilis V, Samantas E, Katsaounis P, Dermitzaki EK, Hatzidaki D, Mavroudis D, Georgoulias V. Br J Cancer EOEO Clinical
286 2016 NSCLC A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer. Kontopodis E, Kotsakis A, Kentepozidis N, Syrigos K, Ziras N, Moutsos M, Filippa G, Mala A, Vamvakas L, Mavroudis D, Georgoulias V, Agelaki S. Cancer Chemother Pharmacol. EOEO Clinical
287 2016 NSCLC Biweekly Carboplatin Plus Gemcitabine as First-Line Treatment of Elderly Patients With Advanced Squamous Non-Small-cell Lung Cancer: A Multicenter Phase I-II Trial by the Hellenic Oncology Research Group. Karampeazis A, Vamvakas L, Kentepozidis N, Polyzos A, Chandrinos V, Rigas G, Christofyllakis C, Kotsakis A, Hatzidaki D, Pallis AG, Georgoulias V. Clin Lung Cancer EOEO Clinical
288 2016 NSCLC Effect of First-Line Treatment on Myeloid-Derived Suppressor Cells’ Subpopulations in the Peripheral Blood of Patients with Non-Small Cell Lung Cancer. Koinis F, Vetsika EK, Aggouraki D, Skalidaki E, Koutoulaki A, Gkioulmpasani M, Georgoulias V, Kotsakis A. J Thorac Oncol. EOEO LAB
289 2016 NSCLC Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG). Matikas A, Kentepozidis Ν, Ardavanis A, Vaslamatzis M, Polyzos A, Emmanouilides Ch, Katsaounis P, Koinis F, Xynogalos S, Christopoulou A, Ziras N, Tegos T, Prinarakis E, Hatzidaki D, Georgoulias V, Kotsakis A Cancer Chemother Pharmacol. EOEO Clinical
290 2017 All tumors Application of data mining techniques and data analysis methods to measure cancer morbidity and mortality data in a regional cancer registry: The case of the island of Crete, Greece. Varlamis I, Apostolakis I, Sifaki-Pistolla D, Dey N, Georgoulias V, Lionis C. Comput Methods Programs Biomed. Athens Laboratory LAB
291 2017 All tumors Classifying circulating tumor cells to monitor cancer progression. Economopoulou P, Georgoulias V, Kotsakis A Expert Rev Mol Diagn. EOEO LAB
292 2017 All tumors Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy. Bakogeorgos M, Georgoulias V. Expert Rev Anticancer Ther. EOEO Clinical
293 2017 Breast Cancer A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer. Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D. Cell Physiol Biochem. EOEO LAB
294 2017 Breast Cancer Association analysis identifies 65 new breast cancer risk loci. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman et al Nature EOEO Clinical
295 2017 Breast Cancer Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, Tzardi M, Mavroudis D, Georgoulias V. Transl Oncol. EOEO LAB
296 2017 Breast Cancer Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer. Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E. Oncotarget. EOEO Clinical
297 2017 Breast Cancer Distinction between breast cancer cell subtypes using third harmonic generation microscopy. Gavgiotaki E, Filippidis G, Markomanolaki H, Kenanakis G, Agelaki S, Georgoulias V, Athanassakis I. J Biophotonics. EOEO Clinical
298 2017 Breast Cancer Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S. Mol Oncol. Laboratory UOC LAB
299 2017 Breast Cancer Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A et al Nat Genet. Laboratory UOC LAB
300 2017 Breast Cancer Implementing neoadjuvant endocrine strategies in ER-positive, HER2-negative breast cancer. Matikas A, Foukakis T, Michalakis I, Georgoulias V. Expert Rev Anticancer Ther. Laboratory UOC LAB
301 2017 Breast Cancer Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Martin M, Holmes FA, Ejlertsen B, et al Lancet Oncol. Laboratory UOC LAB
302 2017 Breast Cancer Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients. Agelaki S, Dragolia M, Markonanolaki H, Alkahtani S, Stournaras C, Georgoulias V, Kallergi G. Oncotarget. Laboratory UOC LAB
303 2017 Breast Cancer Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients. Papadakis GZ, Mavroudis D, Georgoulias V, Souglakos J, Alegakis AK, Samonis G, Bagci U, Makrigiannakis A, Zoras O. Growth Horm IGF Res. Laboratory UOC LAB
304 2017 Lung Cancer Lung cancer and annual mean exposure to outdoor air pollution in Crete, Greece. Sifaki-Pistolla D, Lionis C, Koinis F, Georgoulias V, Tzanakis N; Cancer Registry of Crete (CRC). Eur J Cancer Prev. POGK Clinical
305 2017 Lung Cancer Lung cancer and tobacco smoking in Crete, Greece: reflections from a population-based cancer registry from 1992 to 2013. Sifaki-Pistolla D, Lionis C, Georgoulias V, Kyriakidis P, Koinis F, Aggelaki S, Tzanakis N. Tob Induc Dis. POGK- άλλη κλινική Clinical
306 2017 NSCLC Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. N Engl J Med POGK- άλλη κλινική Clinical
307 2017 NSCLC Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups. Messaritakis I, Kotsakis A, Georgoulias V. J Thorac Dis POGK- άλλη κλινική Clinical
308 2017 NSCLC Docetaxel plus gemcitabine versus gemcitabine in elderly patients with advanced non-small cell lung cancer and use of a geriatric assessment: Lessons from a prematurely closed Hellenic Oncology Research Group randomized phase III study. Karampeazis A, Vamvakas L, Kotsakis A, Christophyllakis C, Kentepozidis N, Chandrinos V, Agelidou A, Polyzos A, Tsiafaki X, Hatzidaki D, Georgoulias V. J Geriatr Oncol POGK- άλλη κλινική Clinical
309 2017 NSCLC Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer. Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V. Cancer Chemother Pharmacol. review Clinical
310 2017 NSCLC Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients. Kotsakis A, Koinis F, Katsarou A, Gioulbasani M, Aggouraki D, Kentepozidis N, Georgoulias V, Vetsika EK. Sci Rep review Clinical
311 2017 NSCLC Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG). Kentepozidis N, Economopoulou P, Christofyllakis C, Chelis L, Polyzos A, Vardakis N, Koinis F, Vamvakas L, Katsaounis P, Kalbakis K, Nikolaou C, Georgoulias V, Kotsakis A. Clin Transl Oncol review Clinical
312 2017 NSCLC Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. Matikas A, Mistriotis D, Georgoulias V, Kotsakis A. Crit Rev Oncol Hematol. review Clinical
313 2017 Ovarian Cancer Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, Lagoudaki E, Giannikaki L, Kalykaki A, Kontopodis E, Saridaki Z, Malamos N, Georgoulias V, Souglakos J. Pharmacogenomics J review Clinical
314 2017 SCLC Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib. Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A. Lung Cancer. Διεθνείς συνεργασίες Clinical
315 2017 SCLC Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer. Messaritakis I, Politaki E, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Kallergi G, Souglakos J, Georgoulias V. PLoS One. Διεθνείς συνεργασίες Clinical
316 2017 SCLC Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group. Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A. Br J Cancer. Διεθνείς συνεργασίες Clinical
317 2017 SCLC TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC) Messaritakis I, Stoltidis D, Kotsakis A, Dermitzaki EK, Koinis F, Lagoudaki E, Koutsopoulos A, Politaki E, Apostolaki S, Souglakos J, Georgoulias V. Sci Rep. Διεθνείς συνεργασίες Clinical
318 2018 All tumors Detection of the T cell activation state using nonlinear optical microscopy. Gavgiotaki E, Filippidis G, Zerva I, Kenanakis G, Archontakis E, Agelaki S, Georgoulias V, Athanassakis I. J Biophotonics. Athens Laboratory LAB
319 2018 Bladder Cancer MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer. Koutsioumpa M, Chen HW, O’Brien N, Koinis F, Mahurkar-Joshi S, Vorvis C, Soroosh A, Luo T, Issakhanian S, Pantuck AJ, Georgoulias V, Iliopoulos D, Slamon DJ, Drakaki A. Mol Cancer Ther. EOEO Clinical
320 2018 Breast Cancer Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. Mol Cancer Ther. EOEO Clinical
321 2018 Breast Cancer ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E Clin Cancer Res. EOEO Clinical
322 2018 Breast Cancer ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E. Clin Cancer Res. EOEO clinical
323 2018 Breast Cancer Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements. Kallergi G, Aggouraki D, Zacharopoulou N, Stournaras C, Georgoulias V, Martin SS. Breast Cancer Res. EOEO clinical
324 2018 Breast Cancer Expression of insulin-like growth factor-1 receptor in circulating tumor cells of patients with breast cancer is associated with patient outcomes. Spiliotaki M, Mavroudis D, Kokotsaki M, Vetsika EK, Stoupis I, Matikas A, Kallergi G, Georgoulias V, Agelaki S. Mol Oncol. EOEO clinical
325 2018 Breast Cancer Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D, Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Breast Cancer Res Treat. EOEO clinical
326 2018 Breast Cancer Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, et al Am J Hum Genet. Laboratory UOC LAB
327 2018 Breast Cancer Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group. Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V. Br J Cancer. Laboratory UOC LAB
328 2018 Breast Cancer Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. Clin Breast Cancer. Laboratory UOC LAB
329 2018 Breast Cancer Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group. Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D. Clin Breast Cancer Laboratory UOC LAB
330 2018 Colorectal Cancer Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer. Messaritakis I, Sfakianaki M, Papadaki C, Koulouridi A, Vardakis N, Koinis F, Hatzidaki D, Georgoulia N, Kladi A, Kotsakis A, Souglakos J, Georgoulias V. Cancer Chemother Pharmacol. Laboratory UOC LAB
331 2018 Colorectal Cancer Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. J Geriatr Oncol. Laboratory UOC LAB
332 2018 Gastric Cancer Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Ann Gastroenterol. Laboratory UOC LAB
333 2018 Gastric Cancer Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group. Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J. Ann Gastroenterol. Laboratory UOC LAB
334 2018 Gastric Cancer Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group. Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V. Ann Gastroenterol. Laboratory UOC LAB
335 2018 Lung Cancer Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial. Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC. JAMA Oncol. Laboratory UOC LAB
336 2018 NSCLC Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. Pharmacogenomics J. POGK- άλλη κλινική LAB
337 2018 NSCLC Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study. Syrigos KN, Georgoulias V, Zarogoulidis K, Makrantonakis P, Charpidou A, Christodoulou C. Anticancer Res. review clinical
338 2018 NSCLC Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. Pelekanou V, Anastasiou E, Bakogeorgou E, Notas G, Kampa M, Garcia-Milian R, Lavredaki K, Moustou E, Chinari G, Arapantoni P, O’Grady A, Georgoulias V, Tsapis A, Stathopoulos EN, Castanas E. Steroids. review clinical
339 2018 NSCLC Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Kallergi G, Vetsika EK, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, Katsarlinos P, Trypaki M, Messaritakis I, Stournaras C, Georgoulias V, Kotsakis A. Ther Adv Med Oncol. review clinical
340 2018 NSCLC Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A. Clin Transl Oncol. άλλο Lab LAB
341 2018 NSCLC Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, Dermitzaki EK, Kontopodis E, Pallis AG, Georgoulias V, Kotsakis A. Clin Transl Oncol. άλλο Lab LAB
342 2018 SCLC Bcl-2 expression in circulating tumor cells (CTCs) of patients with small cell lung cancer (SCLC) receiving front-line treatment. Messaritakis I, Nikolaou M, Politaki E, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulia N, Georgoulias V, Kotsakis A. Lung Cancer. άλλο Lab LAB
343 2018 SCLC Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib. Messaritakis I, Politaki E, Koinis F, Stoltidis D, Apostolaki S, Plataki M, Dermitzaki EK, Georgoulias V, Kotsakis A. Sci Rep. Διεθνείς συνεργασίες Clinical
344 2018 SCLC Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A Lung Cancer. Διεθνείς συνεργασίες Clinical
345 2018 Stomach Small cell carcinoma of the stomach: A report of two cases and a review of the literature. Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N. Mol Clin Oncol. Διεθνείς συνεργασίες Clinical
346 2019 All tumors Detection of the T cell activation state using nonlinear optical microscopy. Gavgiotaki E, Filippidis G, Zerva I, Kenanakis G, Archontakis E, Agelaki S, Georgoulias V, Athanassakis I. J Biophotonics. Athens Laboratory LAB
347 2019 All tumors Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. Vougas K, Sakellaropoulos T, Kotsinas A, Foukas GP, Ntargaras A, Koinis F, Polyzos A, Myrianthopoulos V, Zhou H, Narang S, Georgoulias V, Alexopoulos L, Aifantis I, Townsend PA, Sfikakis P, Fitzgerald R, Thanos D, Bartek J, Petty R, Tsirigos A, Gorgoulis VG. Pharmacol Ther. Athens Laboratory lab
348 2019 All tumors Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Mullane KM, Morrison VA, Camacho LH, Arvin A, McNeil SA, Durrand J, Campbell B, Su SC, Chan ISF, Parrino J, Kaplan SS, Popmihajlov Z, Annunziato PW; V212 Protocol 011 Trial Team. Lancet Infect Dis. Athens Laboratory LAB
349 2019 Breast Cancer Circulating Tumor Cells with Stemness and Epithelial-to-Mesenchymal Transition Features Are Chemoresistant and Predictive of Poor Outcome in Metastatic Breast Cancer. Papadaki MA, Stoupis G, Theodoropoulos PA, Mavroudis D, Georgoulias V, Agelaki S. Mol Cancer Ther. EOEO clinical
350 2019 Breast Cancer First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial. Liu MC, Janni W, Georgoulias V, Yardley DA, Harbeck N, Wei X, McGovern D, Beck R. Cancer Manag Res. EOEO LAB
351 2019 Breast Cancer Genome-wide association study of germline variants and breast cancer-specific mortality. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL et al Br J Cancer. EOEO Clinical
352 2019 Breast Cancer PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study. Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V, Lianidou E. Mol Oncol. EOEO clinical
353 2019 Breast Cancer Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J et al Am J Hum Genet. Laboratory UOC LAB
354 2019 Breast Cancer Prognostic Significance of TWIST1, CD24, CD44, and ALDH1 Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients. Strati A, Nikolaou M, Georgoulias V, Lianidou ES. Cells. Laboratory UOC LAB
355 2019 Breast Cancer The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A, Zacharopoulou N, Alkahtani S, Alarifi S, Stournaras C, Zervakis M, Georgoulias V. Breast Cancer Res. Laboratory UOC LAB
356 2019 colon cancer Loss of LKB1 Protein Expression Correlates with Increased Risk of Recurrence and Death in Patients with Resected, Stage II or III Colon Cancer. Sfakianaki M, Papadaki C, Tzardi M, Trypaki M, Alam S, Lagoudaki ED, Messaritakis I, Zoras O, Mavroudis D, Georgoulias V, Souglakos J. Cancer Res Treat. Laboratory UOC LAB
357 2019 colon cancer Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project. Souglakos J, Boukovinas I, Kakolyris S, Xynogalos S, Ziras N, Athanasiadis A, Androulakis N, Christopoulou A, Vaslamatzis M, Ardavanis A, Emmanouilides C, Bompolaki I, Kourousis C, Makrantonakis P, Christofyllakis C, Athanasiadis E, Kentepozidis N, Karampeazis A, Katopodi U, Anagnosopoulos A, Papadopoulos G, Prinarakis E, Kalisperi A, Mavroudis D, Georgoulias V. Ann Oncol Laboratory UOC LAB
358 2019 Colorectal Cancer Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group. J Geriatr Oncol. Laboratory UOC LAB
359 2019 Colorectal Cancer MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer. Matikas A, Souglakos J, Katsaounis P, Kotsakis A, Kouroupakis P, Pantazopoulos N, Kentepozidis N, Nikolaidi A, Messaritakis I, Tzovara I, Hatzidaki D, Prinarakis E, Georgoulias V. Target Oncol. POGK- άλλη κλινική LAB
360 2019 Head and Neck Cancer Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, et al Lancet. POGK- άλλη κλινική LAB
361 2019 NSCLC Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer. Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, Trypaki M, Tsakalaki E, Sfakianaki M, Hasan B, Stathopoulos E, Georgoulias V, Souglakos J. Pharmacogenomics J. Διεθνείς συνεργασίες clinical
362 2019 NSCLC CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance? Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, Koutsopoulos A, Georgoulias V, Vetsika EK. Ther Adv Med Oncol. Διεθνείς συνεργασίες clinical
363 2019 NSCLC Estrogen receptor-alpha isoforms are the main estrogen receptors expressed in non-small cell lung carcinoma. Pelekanou V, Anastasiou E, Bakogeorgou E, Notas G, Kampa M, Garcia-Milian R, Lavredaki K, Moustou E, Chinari G, Arapantoni P, O’Grady A, Georgoulias V, Tsapis A, Stathopoulos EN, Castanas E. Steroids. Διεθνείς συνεργασίες clinical
364 2019 Ovarian Cancer Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study. Syrios J, Kouroussis C, Kotsakis A, Kentepozidis N, Kontopodis E, Kalbakis K, Vardakis N, Hatzidaki D, Polyzos A, Georgoulias V; GU Working Group of the Hellenic Oncology Research Group (HORG). Minerva Ginecol. Διεθνείς συνεργασίες Clinical
365 2019 SCLC Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment. Messaritakis I, Nikolaou M, Koinis F, Politaki E, Koutsopoulos A, Lagoudaki E, Vetsika EK, Georgoulias V, Kotsakis A. Lung Cancer. Διεθνείς συνεργασίες clinical
366 2020 Breast Cancer BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. Apostolou P, Fostira F, Kouroussis C, Kalfakakou D, Delimitsou A, Agelaki S, Androulakis N, Christodoulou C, Kalbakis K, Kalykaki A, Sanidas E, Papadimitriou C, Vamvakas L, Georgoulias V, Mavroudis D, Yannoukakos D, Konstantopoulou I, Saloustros E. Int J Cancer. Athens Laboratory LAB
367 2020 Breast Cancer Chemotherapy use near the end-of-life in patients with metastatic breast cancer. Edman Kessler L, Sigfridsson J, Hatzidaki D, Bergh J, Foukakis T, Georgoulias V, Matikas A. Breast Cancer Res Treat. Athens Laboratory LAB
368 2020 Breast Cancer CXCR4 and JUNB double-positive disseminated tumor cells are detected frequently in breast cancer patients at primary diagnosis. Kallergi G, Hoffmann O, Bittner AK, Papadimitriou L, Katsarou SD, Zacharopoulou N, Zervakis M, Sfakianakis S, Stournaras C, Georgoulias V, Kimmig R, Kasimir-Bauer S. Ther Adv Med Oncol. Laboratory UOC LAB
369 2020 Breast Cancer Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P et al Nat Genet. POGK clinical
370 2020 Breast Cancer Third Harmonic Generation microscopy distinguishes malignant cell grade in human breast tissue biopsies. Gavgiotaki E, Filippidis G, Tsafas V, Bovasianos S, Kenanakis G, Georgoulias V, Tzardi M, Agelaki S, Athanassakis I. Sci Rep. POGK- άλλη κλινική clinical
371 2020 NSCLC Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, et al Br J Cancer. review clinical
372 2020 NSCLC KMT2C promoter methylation in plasma-circulating tumor DNA is a prognostic biomarker in non-small cell lung cancer. Mastoraki S, Balgkouranidou I, Tsaroucha E, Klinakis A, Georgoulias V, Lianidou E. Mol Oncol. άλλο Lab LAB
373 2020 NSCLC Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. Ioannidis G, Papadaki C, Lagoudaki E, Tzardi M, Trypaki M, Stathopoulos E, Mavroudis D, Georgoulias V, Souglakos J. Anticancer Res. Διεθνείς συνεργασίες clinical
374 2020 Urothelial Cancer Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee JL, De Giorgi U et al Lancet Oncol. Διεθνείς συνεργασίες clinical